异柠檬酸脱氢酶1/2突变急性髓系白血病的管理
综述阐述IDH突变在急性髓系白血病恶性转化中的作用,聚焦靶向IDH1/IDH2突变AML的新型治疗药物,并探讨其对预后的影响。
要点
- 二代测序和突变谱分析广泛应用加深了对AML异质性分子基础的理解。
- 针对FLT3、IDH1和IDH2突变的新型靶向药物已获批用于部分AML患者。
- 综述聚焦靶向IDH1/IDH2突变AML的新型药物及其对预后的影响。
核心结论
- 新型靶向药物为AML患者提供了新的治疗方式,推动治疗模式向个体化医疗转变。
研究设计与样本
- 综述,检索范围未报告。
主要发现
- 二代测序和突变谱分析的广泛应用拓宽了对AML异质性分子基础的理解。
- 基因测序成为标准实践后,已鉴定出多种驱动突变。
- 针对FLT3、IDH1和IDH2突变的新型靶向治疗药物已开发并获批用于携带相应突变的患者亚组。
关键数值与推荐
- 针对FLT3、IDH1和IDH2突变的新型靶向药物已获批用于携带相应突变的患者亚组。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The emergence of next generation sequencing and widespread use of mutational profiling in acute myeloid leukemia (AML) has broadened our understanding of the heterogeneous molecular basis of the disease. Since genetic sequencing has become a standard practice, several driver mutations have been identified. Accordingly, novel targeted therapeutic agents have been developed and are now approved for the treatment of subsets of patients that carry mutations in FLT3, IDH1, and IDH2 [1, 2]. The emergence of these novel agents in AML offers patients a new modality of therapy, and shifts treatment paradigms toward individualized medicine. In this review, we outline the role of IDH mutations in malignant transformation, focus in on a novel group of targeted therapeutic agents directed toward IDH1- and IDH2-mutant AML, and explore their impact on prognosis in patients with AML.
引用
- Fruchtman H, Avigan ZM, Waksal JA, et al. Management of isocitrate dehydrogenase 1/2 mutated acute myeloid leukemia. Leukemia. 2024. PMID: 38600315. doi:10.1038/s41375-024-02246-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。